close

Sucampo Pharmaceuticals, Inc., through its subsidiaries, focuses on the discovery, development, and commercialization of drugs based on prostones in the United States, Europe, and Japan. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system diseases and disorders. The company primarily markets Amitiza for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women. It also offers Rescula (unoprostone isopropyl) for the treatment of glaucoma. In addition, Sucampo Pharmaceuticals is conducting two Phase III pivotal trials of Amitiza for opioid-induced bowel dysfunction; a Phase II proof of concept trial of Cobiprostone for the prevention of non-steroidal anti-inflammatory drug induced ulcers; various preclinical trials of Cobiprostone for cystic fibrosis respiratory symptoms, topical ulcers and wounds, and chronic obstructive pulmonary disease; and a preclinical phase study of SPI-017 for Alzheimer's disease. The company also has various pre-clinical studies of six additional preclinical prostone compounds, including two combination candidates for age-related diseases. Sucampo Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	7.48
Volume	64754
Volume Avg	38988
52 Week High	7.59
52 Week Low	2.75
PE	N/A
PE (group average)	N/A
EPS Year	-0.64
EPS change Q/Q	-13.33%
EPS change Q/Q Yr ago	1000%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-1000%
REV change Q/Q	-1.61%
REV change Q/Q Yr ago	-17.57%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%